pI: 5.6024 |
Length (AA): 362 |
MW (Da): 40967 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 362 | 1yhl (A) | 1 | 362 | 64.00 | 0 | 1 | 1.97 | -2.49 |
2 | 362 | 4jzx (A) | 2 | 362 | 99.99 | 0 | 1 | 2.25374 | -1.64 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127590)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G17190 | farnesyl diphosphate synthase 2 |
Arabidopsis thaliana | AT5G47770 | farnesyl diphosphate synthase 1 |
Babesia bovis | BBOV_I000120 | farnesyl pyrophosphate synthetase, putative |
Brugia malayi | Bm1_54695 | Polyprenyl synthetase family protein |
Candida albicans | CaO19.11967 | similar to S. cerevisiae ERG20 (YJL167W) farnesyl diphosphate synthetase (FPP synthetase) |
Candida albicans | CaO19.4491 | similar to S. cerevisiae ERG20 (YJL167W) farnesyl diphosphate synthetase (FPP synthetase) |
Caenorhabditis elegans | CELE_R06C1.2 | Protein FDPS-1 |
Cryptosporidium hominis | Chro.40285 | farnesyl pyrophosphate synthase |
Cryptosporidium parvum | cgd4_2550 | putative farnesyl pyrophosphate synthase |
Dictyostelium discoideum | DDB_G0268742 | hypothetical protein |
Dictyostelium discoideum | DDB_G0278735 | FDP synthase |
Dictyostelium discoideum | DDB_G0278823 | hypothetical protein |
Drosophila melanogaster | Dmel_CG12389 | Farnesyl pyrophosphate synthase |
Echinococcus granulosus | EgrG_001040000 | farnesyl pyrophosphate synthase |
Echinococcus multilocularis | EmuJ_001040000 | farnesyl pyrophosphate synthase |
Giardia lamblia | GL50803_6633 | Farnesyl diphosphate synthase |
Homo sapiens | ENSG00000160752 | farnesyl diphosphate synthase |
Leishmania braziliensis | LbrM.22.1240 | farnesyl pyrophosphate synthase |
Leishmania donovani | LdBPK_221210.1 | farnesyl pyrophosphate synthase |
Leishmania infantum | LinJ.22.1210 | farnesyl pyrophosphate synthase |
Leishmania major | LmjF.22.1360 | farnesyl pyrophosphate synthase |
Leishmania mexicana | LmxM.22.1360 | farnesyl pyrophosphate synthase, putative |
Loa Loa (eye worm) | LOAG_06272 | polyprenyl synthetase |
Mus musculus | ensembl-mmu:ENSMUSG00000059743 | farnesyl diphosphate synthetase |
Mycobacterium tuberculosis | Rv2173 | Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) |
Mycobacterium ulcerans | MUL_0373 | geranylgeranyl pyrophosphate synthase |
Mycobacterium ulcerans | MUL_3516 | geranylgeranyl pyrophosphate synthase |
Neospora caninum | NCLIV_048200 | hypothetical protein |
Oryza sativa | 4337261 | Os04g0657300 |
Oryza sativa | 4337260 | Os04g0657100 |
Oryza sativa | 4324245 | Os01g0703400 |
Oryza sativa | 4339489 | Os05g0543400 |
Plasmodium berghei | PBANKA_0919800 | geranylgeranyl pyrophosphate synthase, putative |
Plasmodium falciparum | PF3D7_1128400 | geranylgeranyl pyrophosphate synthase, putative |
Plasmodium knowlesi | PKNH_0926500 | geranylgeranyl pyrophosphate synthase, putative |
Plasmodium vivax | PVX_092040 | geranylgeranyl pyrophosphate synthase |
Plasmodium yoelii | PY05919 | farnesyl pyrophosphate synthase |
Saccharomyces cerevisiae | YJL167W | bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase |
Schistosoma japonicum | Sjp_0216390 | ko:K00787 dimethylallyltranstransferase [EC2.5.1.1], putative |
Schistosoma mansoni | Smp_070710 | farnesyl pyrophosphate synthase |
Schmidtea mediterranea | mk4.033514.01 | |
Schmidtea mediterranea | mk4.003779.02 | Farnesyl pyrophosphate synthase |
Schmidtea mediterranea | mk4.025052.00 | |
Trypanosoma brucei gambiense | Tbg972.7.3690 | farnesyl pyrophosphate synthase, putative |
Trypanosoma brucei | Tb927.7.3360 | farnesyl pyrophosphate synthase |
Trypanosoma congolense | TcIL3000_7_2560 | farnesyl pyrophosphate synthase |
Trypanosoma cruzi | TcCLB.511823.70 | farnesyl pyrophosphate synthase |
Trypanosoma cruzi | TcCLB.508323.9 | farnesyl pyrophosphate synthase, putative |
Toxoplasma gondii | TGME49_224490 | polyprenyl synthetase superfamily protein |
Theileria parva | TP03_0857 | farnesyl pyrophosphate synthetase, putative |
Trichomonas vaginalis | TVAG_150090 | geranylgeranyl pyrophosphate synthase, putative |
Trichomonas vaginalis | TVAG_388030 | geranylgeranyl pyrophosphate synthase, putative |
Trichomonas vaginalis | TVAG_353270 | geranylgeranyl diphosphate synthase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.3360 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.3360 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.3360 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.7.3360 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_R06C1.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_R06C1.2 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_R06C1.2 | Caenorhabditis elegans | sterile | wormbase |
YJL167W | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0919800 | Plasmodium berghei | Essential | plasmo |
TGME49_224490 | Toxoplasma gondii | Essentiality uncertain | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania donovani | 27181 335042 335833 335834 530570 534274 536350 536351 570944 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates; Drug: 109552-15-0; Drug: (Alendronate) 129318-43-0. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, homologue LmjF22.1360) inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions); Q0GKD7_LEIDO; . | References: | 11850291 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 27181 335042 335833 335834 530570 534274 536350 536351 570944 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates; Drug: 109552-15-0; Drug: (Alendronate) 129318-43-0. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, homologue LmjF22.1360) inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions); Q0GKD7_LEIDO; . | References: | 11850291 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania amazonensis | 27181 335833 570944 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates; Drug: 109552-15-0. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, homologue LmjF22.1360) inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions); Q0GKD7_LEIDO; . | References: | 12089677 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 27181 335833 570944 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates; Drug: 109552-15-0. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, homologue LmjF22.1360) inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions); Q0GKD7_LEIDO; . | References: | 12089677 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from in-silico analysis (ECO:0000043) | Leishmania major | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, LmjF22.1360) inhibitors (designed via comparative molecular similarity indices analysis [COMSIA]) leads to reduced enzyme activity in vitro; Bisphosphonate class. | References: | 14613320 15828834 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates. chemical inhibition with farnesyl pyrophosphate synthase (2.5.1.10, LmjF22.1360) inhibitors (designed via comparative molecular similarity indices analysis [COMSIA]) leads to reduced enzyme activity in vitro; Bisphosphonate class. | References: | 14613320 15828834 | |
growth (GO:0040007) | drug insensitive (PATO:0000528) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from over expression (ECO:0000120) | Leishmania major | 335042 530570 534274 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates. overexpression of recombinant enzyme confers resistance to FPPS inhibitors; . | References: | 16835450 | |
growth (GO:0040007) | drug insensitive (PATO:0000528) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | 335042 530570 534274 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: Bisphosphonates. overexpression of recombinant enzyme confers resistance to FPPS inhibitors; . | References: | 16835450 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.8
Compound | Source | Reference |
---|---|---|
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
ChEMBL23 | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma cruzi | farnesyl pyrophosphate synthase, putative | Compounds | References |
Toxoplasma gondii | polyprenyl synthetase superfamily protein | Compounds | References |
Trypanosoma cruzi | farnesyl pyrophosphate synthase | Compounds | References |
Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | Compounds | References |
Leishmania donovani | farnesyl pyrophosphate synthase | Compounds | References |
Homo sapiens | farnesyl diphosphate synthase | Compounds | References |
8 literature references were collected for this gene.